Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merlin L Robb

Showing results (301-310 of 358) with videos related to

Pageof 36
Sort By:
Plos Pathogens|September 4, 2020
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challengeKier Om, Dominic Paquin-Proulx, Maria Montero, et al.
Cells|August 25, 2019
Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 InfectionSodsai Tovanabutra, Rujipas Sirijatuphat, Phuc T Pham, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Nature Medicine|April 3, 2020
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruptionDonn J Colby, Michal Sarnecki, Dan H Barouch, et al.
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
JCI Insight|May 8, 2023
ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination aloneMargaret C Costanzo, Dominic Paquin-Proulx, Alexandra Schuetz, et al.
Vaccine|May 31, 2011
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsDan H Barouch, Sandra V Kik, Gerrit J Weverling, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
Cell Host & Microbe|March 4, 2021
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodiesSamantha M Townsley, Gina C Donofrio, Ningbo Jian, et al.
Science Translational Medicine|July 17, 2015
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisitionHeather A Prentice, Georgia D Tomaras, Daniel E Geraghty, et al.
Pageof 36

Showing results (301-310 of 358) with videos related to

Sort By:
Pageof 36
Plos Pathogens|September 4, 2020
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challengeKier Om, Dominic Paquin-Proulx, Maria Montero, et al.
Cells|August 25, 2019
Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 InfectionSodsai Tovanabutra, Rujipas Sirijatuphat, Phuc T Pham, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Nature Medicine|April 3, 2020
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruptionDonn J Colby, Michal Sarnecki, Dan H Barouch, et al.
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
JCI Insight|May 8, 2023
ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination aloneMargaret C Costanzo, Dominic Paquin-Proulx, Alexandra Schuetz, et al.
Vaccine|May 31, 2011
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsDan H Barouch, Sandra V Kik, Gerrit J Weverling, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
Cell Host & Microbe|March 4, 2021
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodiesSamantha M Townsley, Gina C Donofrio, Ningbo Jian, et al.
Science Translational Medicine|July 17, 2015
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisitionHeather A Prentice, Georgia D Tomaras, Daniel E Geraghty, et al.
Pageof 36